Skip to main content
Log in

Transcatheter arterial infusion chemotherapy with cisplatin–lipiodol suspension in patients with hepatocellular carcinoma

  • Original Article—Liver, Pancreas, and Biliary Tract
  • Published:
Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Purpose

The aim of this study was to investigate the antitumor efficacy of treatment, identify prognostic factors, and construct a prognostic index in patients with hepatocellular carcinoma treated by transcatheter arterial infusion chemotherapy (TAI) using cisplatin suspended in lipiodol.

Methods

We analyzed the outcomes in a total of 94 consecutive patients with previously untreated hepatocellular carcinoma who were treated by TAI using cisplatin suspended in lipiodol.

Results

Twenty-seven patients (29%) showed complete response and 21 patients (22%) showed partial response, with an overall response rate of 51% (95% confidence interval, 41–61%). The median survival time was 2.5 years and the proportions of survivors at 1, 2, and 5 years were 81.6, 65.2, and 18.3%, respectively. The results of multivariate analysis indicated a significant association of serum albumin ≥3.0 g/dL, maximum tumor size ≤3.0 cm, absence of ascites, and unilateral distribution of the tumors with a favorable survival. For clinical application, we also propose a prognostic index based on a combination of these prognostic factors. Based on this index, the patients were classified into three groups: those with good, intermediate, and poor prognosis. The median survival times in these three groups were 4.3, 2.7, and 1.1 years, respectively (p < 0.01).

Conclusions

TAI with cisplatin suspended in lipiodol exhibited favorable tumor efficacy and survival in patients with hepatocellular carcinoma. The prognostic factors identified and the index proposed based on these factors may be useful for predicting life expectancy, determining treatment strategies, and designing future clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Abbreviations

HCC:

Hepatocellular carcinoma

TAE:

Transcatheter arterial chemoembolization

TAI:

Transcatheter arterial infusion chemotherapy

CT:

Computed tomography

AFP:

Serum alpha-fetoprotein

PIVKA II:

Protein induced by vitamin K absence or antagonist-II

CR:

Complete response

PR:

Partial response

References

  1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–17.

    Article  PubMed  Google Scholar 

  2. Cammà C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology. 2002;224:47–54.

    Article  PubMed  Google Scholar 

  3. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429–42.

    Article  CAS  PubMed  Google Scholar 

  4. Lin DY, Liaw YF, Lee TY, Lai CM. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma—a randomized controlled trial. Gastroenterology. 1988;94:453–6.

    CAS  PubMed  Google Scholar 

  5. Pelletier G, Roche A, Ink O, Anciaux ML, Derhy S, Rougier P, et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol. 1990;11:181–4.

    Article  CAS  PubMed  Google Scholar 

  6. Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med. 1995;332:1256–61.

    Google Scholar 

  7. Pelletier G, Ducreux M, Gay F, Luboinski M, Hagege H, Dao T, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. J Hepatol. 1998;29:129–34.

    Article  CAS  PubMed  Google Scholar 

  8. Bruix J, Llovet JM, Castells A, Montana X, Bru C, Ayuso MC, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized controlled trial in a single institution. Hepatology. 1998;27:1578–83.

    Article  CAS  PubMed  Google Scholar 

  9. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164–71.

    Article  CAS  PubMed  Google Scholar 

  10. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734–9.

    Article  PubMed  Google Scholar 

  11. Schwartz JD, Beutler AS. Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials-II: systemic and local non-embolization-based therapies in unresectable and advanced hepatocellular carcinoma. Anticancer Drugs. 2004;15:439–52.

    Article  CAS  PubMed  Google Scholar 

  12. Minagawa M, Makuuchi M. Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. World J Gastroenterol. 2006;12:7561–7.

    CAS  PubMed  Google Scholar 

  13. Imaeda T, Yamawaki Y, Seki M, Goto H, Iinuma G, Kanematsu M, et al. Lipiodol retention and massive necrosis after lipiodol-chemoembolization of hepatocellular carcinoma: correlation between computed tomography and histopathology. Cardiovasc Intervent Radiol. 1993;16:209–13.

    Article  CAS  PubMed  Google Scholar 

  14. Takayasu K, Shima Y, Muramatsu Y, Moriyama N, Yamada T, Makuuchi M, et al. Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology. 1987;163:345–51.

    CAS  PubMed  Google Scholar 

  15. Okusaka T, Okada S, Ueno H, Ikeda M, Yoshimori M, Shimada K, et al. Evaluation of the therapeutic effect of transcatheter arterial embolization for hepatocellular carcinoma. Oncology. 2000;58:293–9.

    Article  CAS  PubMed  Google Scholar 

  16. Okusaka T, Sato T, Hinotsu S, Shioyama Y, Kasugai H, Tanaka K, et al. Transarterial infusion chemotherapy alone versus transarterial chemoembolization for the treatment of hepatocellular carcinoma: results of a multicenter randomized phase III trial. J Clin Oncol 2007 ASCO Annual Meeting Proceedings. 2007;25:18S (abstr 4643).

  17. Ikeda M, Maeda S, Shibata J, Muta R, Ashihara H, Tanaka M, et al. Transcatheter arterial chemotherapy with and without embolization in patients with hepatocellular carcinoma. Oncology. 2004;66:24–31.

    Article  CAS  PubMed  Google Scholar 

  18. Okusaka T, Okada S, Ueno H, Ikeda M, Iwata R, Furukawa H, et al. Transcatheter arterial embolization with zinostatin stimalamer for hepatocellular carcinoma. Oncology. 2002;62:228–33.

    Article  CAS  PubMed  Google Scholar 

  19. Yamasaki T, Kimura T, Kurokawa F, Aoyama K, Ishikawa T, Tajima K, et al. Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy. J Gastroenterol. 2005;40:70–8.

    Article  CAS  PubMed  Google Scholar 

  20. Uka K, Aikata H, Takaki S, Miki D, Kawaoka T, Jeong SC, et al. Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. J Gastroenterol. 2007;42:845–53.

    Article  CAS  PubMed  Google Scholar 

  21. Yoshikawa M, Ono N, Yodono H, Ichida T, Nakamura H. Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma. Hepatol Res. 2008;38:474–83.

    Article  CAS  PubMed  Google Scholar 

  22. Lladó L, Virgili J, Figueras J, Valls C, Dominguez J, Rafecas A, et al. A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Cancer. 2000;88:50–7.

    Article  PubMed  Google Scholar 

  23. Ikeda M, Okada S, Yamamoto S, Sato T, Ueno H, Okusaka T, et al. Prognostic factors in patients with hepatocellular carcinoma treated by transcatheter arterial embolization. Jpn J Clin Oncol. 2002;32:455–60.

    Article  PubMed  Google Scholar 

  24. Changchien CS, Chen CL, Yen YH, Wang JH, Hu TH, Lee CM, et al. Analysis of 6381 hepatocellular carcinoma patients in southern Taiwan: prognostic features, treatment outcome, and survival. J Gastroenterol. 2008;43:159–70.

    Article  CAS  PubMed  Google Scholar 

  25. Shibata J, Fujiyama S, Sato T, Kishimoto S, Fukushima S, Nakano M. Hepatic arterial injection chemotherapy with cisplatin suspended in an oily lymphographic agent for hepatocellular carcinoma. Cancer. 1989;64:1586–94.

    Article  CAS  PubMed  Google Scholar 

  26. Yoshikawa M, Saisho H, Ebara M, Iijima T, Iwama S, Endo F, et al. A randomized trial of intrahepatic arterial infusion of 4′-epidoxorubicin with lipiodol versus 4′-epidoxorubicin alone in the treatment of hepatocellular carcinoma. Cancer Chemother Pharmacol. 1994;33(Suppl):S149–52.

    Article  PubMed  Google Scholar 

  27. Okusaka T, Okada S, Nakanishi T, Fujiyama S, Kubo Y. Phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in patients with hepatocellular carcinoma. Invest New Drugs. 2004;22:169–76.

    Article  CAS  PubMed  Google Scholar 

  28. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985;56:918–28.

    Article  CAS  PubMed  Google Scholar 

  29. Pugh RNH, Murry-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646–9.

    Article  CAS  PubMed  Google Scholar 

  30. Luo KZ, Itamoto T, Amano H, Oshita A, Ushitora Y, Tanimoto Y, et al. Comparative study of the Japan Integrated Stage (JIS) and modified JIS score as a predictor of survival after hepatectomy for hepatocellular carcinoma. J Gastroenterol. 2008;43:369–77.

    Article  CAS  PubMed  Google Scholar 

  31. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Yutaka Sasaki.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ikeda, M., Maeda, S., Ashihara, H. et al. Transcatheter arterial infusion chemotherapy with cisplatin–lipiodol suspension in patients with hepatocellular carcinoma. J Gastroenterol 45, 60–67 (2010). https://doi.org/10.1007/s00535-009-0109-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00535-009-0109-8

Keywords

Navigation